Living-donor liver transplantation for non-resectable colorectal liver metastases: protocol for a multicentric, single-arm study.

ABSTRACT:

Introduction

The only treatment for non-resectable colorectal liver metastasis (CRLM) is medical therapy, and the overall survival (OS) rate at 3 and 5 years is approximately 30%-40% and less than 10%, respectively. In 2020, a group in Norway reported that liver transplantation for non-resectable CRLM improved the 5-year OS rate to up to 83%. Clinical trials have been launched since that report was published, but most have involved deceased-donor liver transplantation rather than living-donor liver transplantation. Our study will assess the efficacy and safety of living-donor liver transplantation for patients with non-resectable CRLM.

Methods and analysis

This is an investigator-driven, multicentre, prospective, single-arm study involving 11 university hospitals in Japan. P

SUBMITTER: Fukumitsu K 

PROVIDER: S-EPMC11580313 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature